Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2021-04-23 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力独立董事对第七届董事会第22次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various matters discussed at the 22nd meeting of the 7th Board of Directors of a company. It covers opinions on profit distribution, merger and acquisition progress, internal control evaluation, related party transactions, guarantees for subsidiaries, reappointment of the accounting firm, accounting policy changes, asset purchase by a subsidiary, board election, and share repurchase. The document is a formal opinion letter from independent directors rather than a full financial report or announcement. It does not contain financial statements or detailed financial data but provides governance-related opinions and approvals on corporate actions and board matters. This fits best under Board/Management Information (MANG), as it relates to board meeting matters and independent directors' opinions on governance and management decisions.
2021-04-23 Chinese
天士力关于控股股东部分股份解质押及质押的公告
Share Issue/Capital Change Classification · 95% confidence The document is a public announcement regarding the pledge and release of shares by the controlling shareholder of the company. It details the number of shares pledged, released, and the proportion of total shares involved. It also discusses the risk management measures related to the share pledge. There is no financial data, no report attached or referenced as being published, and no mention of an annual or interim report. The document is a regulatory announcement about share pledging activities, which fits the category of Share Issue/Capital Change (SHA) as it relates to changes in share pledging status, a capital structure matter. The document length is 2839 characters, which is relatively short and consistent with an announcement rather than a full report.
2021-03-05 Chinese
大信会计师事务所出具的关于重大资产出售的审计报告
Audit Report / Information Classification · 100% confidence The document is titled as an "审计报告" (Audit Report) issued by a certified public accounting firm for 重庆医药集团(天津)医药商业有限公司. It contains detailed audit opinions, responsibilities of management and auditors, and extensive financial statement notes including balance sheets and accounting policies. The report is dated 2021-02-27 and covers the financial position as of 2020-07-31. The content is consistent with a standalone audit report rather than a full annual report or other filing types. The length is substantial (15,000 characters), and it contains actual financial data and audit opinions, not just an announcement or certification. Therefore, the document fits the category of Audit Report / Information (AR).
2021-03-03 Chinese
天士力关于重大资产出售之过渡期损益情况的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the transitional period profit and loss situation related to a major asset sale by the company Tianjin Tasly Pharmaceutical Group Co., Ltd. It details the audit results and the net asset changes during the transitional period of the asset sale transaction. The document references audit reports but does not contain the full audit report itself, nor does it present comprehensive financial statements or a full annual or interim report. It is a specific announcement about the asset sale and related audit findings, which fits best under a Regulatory Filing (RNS) as it is a regulatory announcement about a transaction and audit results rather than a full audit report or financial report. The document length is short (1458 characters), and it is an announcement rather than the full report itself.
2021-03-03 Chinese
天士力关于股票回购实施结果暨股份变动的公告
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement from the company regarding the results of a stock repurchase program and the related changes in shareholding. It details the approval, implementation, and completion of the stock buyback, including the number of shares repurchased, prices, and the intended use of the repurchased shares (for an equity incentive plan). It also confirms no insider trading occurred during the repurchase period and provides a table showing shareholding changes before and after the buyback. The document is not a financial report or earnings release but a specific announcement about the company's transaction in its own shares. Therefore, it fits the category of 'Transaction in Own Shares' (POS). The document length is 1565 characters, which is consistent with an announcement rather than a full report. Confidence is high due to clear content matching the POS category.
2021-02-24 Chinese
天士力关于全资子公司药品氯氮平片通过仿制药一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the company's board regarding the approval of a pharmaceutical product by a regulatory authority (国家药品监督管理局). It details the product's specifications, approval status, and potential impact on the company. The document is short (935 characters) and serves as a formal public announcement rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed regulatory filings beyond the announcement itself. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2021-02-18 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.